Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
Launched by ANNA STANHEWICZ, PHD · Jun 14, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how a medication called metformin can help improve blood vessel function in women who have experienced gestational diabetes, which is a type of diabetes that can occur during pregnancy. The researchers want to understand the reasons behind the problems with blood vessels in these women and see if metformin could be a useful treatment before any further health issues develop.
To participate in this study, women need to be between 12 weeks and 5 years after having their baby and either have a history of gestational diabetes or have had a healthy pregnancy. However, women who currently have diabetes, are pregnant, smoke, or have certain heart or metabolic conditions cannot join the trial. If eligible, participants will be able to receive treatment and contribute to valuable research that could improve health outcomes for others in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • ≥12 weeks and ≤5 years postpartum
- • history of GDM or healthy pregnancy
- Exclusion Criteria:
- • prediabetes or diabetes (HbA1c ≥5.7%)
- • current tobacco use
- • cardiovascular or metabolic disease
- • cardiovascular or metabolic medication
- • history of hypertension during pregnancy
- • current pregnancy
About Anna Stanhewicz, Phd
Dr. Anna Stanhewicz is a distinguished clinical trial sponsor with a robust background in biomedical research and a focus on innovative therapeutic interventions. Her expertise spans across cardiovascular health, metabolic disorders, and translational medicine, enabling her to effectively lead and oversee clinical studies aimed at advancing patient care. With a commitment to rigorous scientific methodology and ethical standards, Dr. Stanhewicz fosters collaborative environments that drive successful trial outcomes. Her leadership not only emphasizes the importance of patient safety and well-being but also aims to contribute valuable insights to the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Patients applied
Trial Officials
Anna Stanhewicz, PhD
Principal Investigator
University of Iowa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported